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LETTERS
Multidrug-
Resistant Typhoid 
Fever Outbreak in 
Travelers Returning 
from Bangladesh 
To the Editor: Enteric fever 
(typhoid and paratyphoid fever) is a 
systemic infection caused by several 
Salmonella enterica serotypes includ-
ing S. Typhi and S. Paratyphi A. The 
Indian subcontinent, which has the 
highest incidence of the disease world-
wide, is also an epicenter of enteric 
fever caused by multidrug-resistant 
(MDR; resistant to chloramphenicol, 
ampicillin, and trimethoprim-sulfa-
methoxazole) and nalidixic acid–re-
sistant (NAR) strains, i.e., strains with 
decreased susceptibility to ciproﬂ  oxa-
cin (1–3). A total of 57% of S. Typhi 
strains isolated at a referral center in 
Dhaka, Bangladesh, in 2005 were 
MDR and NAR (4).
More than 80% of 442 enteric 
fever cases reported in Japan dur-
ing 2001–2004 were imported (5). 
Most Japanese persons, especially the 
younger generation, are not immune 
to enteric fever as are persons living in 
other industrialized countries.
Although the proportion of enter-
ic fever cases related to international 
travel has increased in industrialized 
countries, few outbreaks of enteric 
fever have been reported in travel-
ers (6,7). We describe an outbreak 
of MDR and NAR typhoid fever in 
young Japanese travelers returning 
from Bangladesh. This outbreak high-
lights the need for standard treatments 
for MDR and NAR enteric fever.
Ten Japanese junior and senior 
high school students living in the To-
kyo metropolitan area took part in a 
9-day study tour to Dhaka in March–
April, 2004. They were escorted by 2 
Japanese college students and a 28-
year-old Japanese instructor. The 13 
participants returned to Japan on April 
4, 2004. The purpose of the study tour 
was to acquire knowledge about street 
children in Dhaka. The students stayed 
at a guesthouse and visited orphanag-
es in the city. The itinerary included a 
visit to a local home, where the family 
served them a meal. They shared all 
their meals during the tour.
Fever and diarrhea developed in 
2 participants on April 3 and 5, and 
these symptoms were later shown to 
be caused by shigellosis. On April 19, 
the index patient became febrile. From 
that date until April 28, there were 6 
conﬁ  rmed and 2 probable typhoid fe-
ver cases reported in the 13 tour par-
ticipants, resulting in an attack rate of 
62%. The median age of the patients 
was 17 years (range 12–28 years); 5 
patients were female. No other cases 
of typhoid fever were reported in that 
period in Japan. 
All 6 S. Typhi isolates were Vi-
phage type E9. These isolates were 
also MDR and NAR, and the MIC 
for ciproﬂ   oxacin for the 6 isolates 
was 0.38 μg/mL. It was strongly sus-
pected that a single-point exposure to 
S. Typhi occurred in the tour partici-
pants during their stay in Bangladesh 
and caused this exceptional outbreak. 
None of the participants had received 
a typhoid vaccination.
The 8 patients were admitted to 
5 hospitals in the Tokyo metropolitan 
area. Four different antimicrobial drug 
regimens were used on the basis of the 
age of the patients and the hospital in 
which each patient was hospitalized 
(Table). Four patients at 2 hospitals 
who received ﬂ  uoroquinolone mono-
therapies were given other regimens 
on days 4–6 of treatment because of 
concern of treatment failure. The me-
dian fever clearance time was 6 days 
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Table. Characteristics of 8 case-patients with typhoid fever, Bangladesh, 2004* 
Case-
patient†
Age, y/ 
sex 
Date of 
onset
Vi-phage
type 
Ciprofloxacin
MIC, μg/mL 
Cefotaxime MIC, 
μg/mL Treatment‡ FCT, d
1C 28/F Apr 19  E9 0.38 0.094 Ciprofloxacin 500 mg 2× a day for 3 d, 
cefotaxime 1 g every 12 h + tosulfoxacin 
300 mg 2× a day for 11 d 
4§
2C 17/F Apr 20  E9 0.38 0.094 Levofloxacin 200 mg 2× a day for 14 d  6
3C 17/F Apr 21  E9 0.38 0.094 Ciprofloxacin 500 mg 2× a day for 3 d,  
cefotaxime 1 g every 12 h + tosulfoxacin 
300 mg 2× a day for 11 d 
3
4P 19/F Apr 21  NA NA NA Levofloxacin 200 mg 2× a day for 3 d, 
cefotaxime 1 g every 12 h + tosulfoxacin 
300 mg 2× a day for 13 d 
12
5C 12/M Apr 22  E9 0.38 0.094 Azithromycin 1 g for 1 d, 500 mg a day for  
2 d; norfloxacin 250 mg 3× a day for 11 d 
7
6C 16/F Apr 23  E9 0.38 0.094 Levofloxacin 500 mg a day for 14 d  5
7C 19/M Apr 23  E9 0.38 0.064 Ciprofloxacin 500 mg 2× a day for 5 d, 
ceftriaxone 2 g every 12 h for 16 d 
6
8P 15/M Apr 28  NA NA NA Levofloxacin 200 mg 2× a day for 18 d  7
*MICs were determined by E-test (AB Biodisk, Solna, Sweden). MICs of chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid 
were >256 μg/mL, >256 μg/mL, >32 μg/mL, and >256 μg/mL, respectively. FCT, fever clearance time (time from the start of treatment until the body 
temperature reached 37.5°C and remained at 37.5°C for 48 h); NA:, not available.  
†C, confirmed case, i.e., a patient with fever (>38°C) for >3 d and a laboratory-confirmed positive blood culture for Salmonella enterica serotype Typhi; P, 
probable case, i.e., a patient with fever (>38°C) for >3 d without isolation of S. Typhi. 
‡All fluoroquinolones were given orally. Tosufloxacin is a fluoroquinolone with properties similar to those of levofloxacin. 
§Fever relapsed 15 d after completion of treatment. Retreatment with tosufloxacin, 600 mg/d for 23 d, was successful. LETTERS
(range 3–12 days). No complications 
occurred during any of the treatment 
regimens. Although a relapse occurred 
15 days after completion of treatment 
in the oldest patient, who had received 
cefotaxime and oral tosuﬂ  oxacin, re-
treatment cured the infection without 
fecal carriage.
The high attack rate may reﬂ  ect 
the high sensitivity of adolescents to 
typhoid fever and the high level of 
bacterial contamination in food the 
participants had eaten during travel 
(2). Although the meal at the private 
home was suspected as the source of 
infection, we could not determine the 
exact cause of this outbreak.
The optimum treatment for MDR 
and NAR enteric fever has not yet 
been established. A third-generation 
cephalosporin or high doses of ﬂ  uoro-
quinolones (e.g., ciproﬂ  oxacin, 20 mg/
kg/day or levoﬂ  oxacin, 10 mg/kg/day) 
for 10–14 days are the drugs of choice 
(1,2). Azithromycin is also a promising 
agent (8). However, for any of the reg-
imens, the mean fever clearance times 
are relatively long (≈7 days), and the 
relapse rates are high (1). Although all 
6 isolates showed reduced susceptibil-
ity to ciproﬂ  oxacin, a long course (14 
days) of ﬂ  uoroquinolones was still ef-
fective in this outbreak. However, cli-
nicians should be aware of treatment 
failure in MDR and NAR enteric fever 
(3). The combination therapy of cefo-
taxime and a ﬂ  uoroquinolone used in 
3 patients has not shown greater ef-
ﬁ  cacy than monotherapies. In fact, 1 
patient who received this combination 
therapy experienced a relapse.
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Human Rabies 
Cluster Following 
Badger Bites, 
People’s Republic 
of China
To the Editor: From February 
2002 to April 2004, 7 rural residents of 
Coteau County (population 450,000) 
in western Zhejiang Province in east-
ern People’s Republic of China died of 
rabies following badger bites (Figure). 
In this county, 89% of residents are 
farmers. The county covers 4,475 km2, 
and the terrain is mountainous. No 
other cases of human rabies had been 
reported from this county since 1986. 
We investigated the cluster to ascertain 
characteristics of these exposures.
Rabies testing was not readily 
available. In China, the national case 
deﬁ  nition is based on clinical compat-
ibility with appropriate animal expo-
sure. Doctors are required to report 
rabies according to a general case 
description published by the Ministry 
of Health. Laboratory conﬁ  rmation is 
not generally performed. We deﬁ  ned 
a rabies case as any person from Co-
teau County in whom rabies was di-
agnosed by a physician from February 
2002 through March 31, 2007. We 
interviewed family members of case-
patients and neighbors about the char-
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